Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing-Based In Vitro Diagnostics Intended To Aid in the Diagnosis of Suspected Germline Diseases; Guidance for Stakeholders and Food and Drug Administration Staff; Availability, 16106-16108 [2018-07687]
Download as PDF
<![CDATA[
daltland on DSKBBV9HB2PROD with NOTICES
16106
Federal Register / Vol. 83, No. 72 / Friday, April 13, 2018 / Notices
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. All electronic and
written submissions submitted to the
Docket (see the ADDRESSES section) on
or before April 26, 2018, will be
provided to the committee. Oral
presentations from the public will be
scheduled between approximately 1:15
p.m. and 2:15 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before April 24,
2018. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by April 25, 2018.
Persons attending FDAs advisory
committee meetings are advised that
FDA is not responsible for providing
access to electrical outlets.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Cindy Chee
(see FOR FURTHER INFORMATION CONTACT)
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 10, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–07747 Filed 4–12–18; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:41 Apr 12, 2018
Jkt 244001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–D–1270]
Considerations for Design,
Development, and Analytical Validation
of Next Generation Sequencing-Based
In Vitro Diagnostics Intended To Aid in
the Diagnosis of Suspected Germline
Diseases; Guidance for Stakeholders
and Food and Drug Administration
Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of the final
guidance entitled ‘‘Considerations for
Design, Development, and Analytical
Validation of Next Generation
Sequencing (NGS)-Based In Vitro
Diagnostics (IVDs) Intended to Aid in
the Diagnosis of Suspected Germline
Diseases; Guidance for Stakeholders and
Food and Drug Administration Staff.’’
FDA’s vision is that NGS-based tests can
be developed, validated, and offered for
clinical use through a process that
leverages appropriate standards, quality
systems controls, and community
assessment of clinical validity to
streamline the premarket review
process. This guidance provides
recommendations for designing,
developing, and establishing analytical
performance for NGS-based tests used
for whole exome human DNA
sequencing (WES) or targeted human
DNA sequencing intended to aid in the
diagnosis of symptomatic individuals
with suspected germline diseases or
other conditions. These
recommendations are based on FDA’s
understanding of the tools and
processes needed to run an NGS-based
test along with the design and analytical
validation considerations appropriate
for such tests.
DATES: The announcement of the
guidance is published in the Federal
Register on April 13, 2018.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–D–1270 for ‘‘Considerations for
Design, Development, and Analytical
Validation of Next Generation
Sequencing (NGS)-Based In Vitro
Diagnostics (IVDs) Intended to Aid in
the Diagnosis of Suspected Germline
Diseases; Guidance for Stakeholders and
Food and Drug Administration Staff.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
E:\FR\FM\13APN1.SGM
13APN1
daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 72 / Friday, April 13, 2018 / Notices
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
An electronic copy of the guidance
document is available for download
from the internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Considerations for
Design, Development, and Analytical
Validation of Next Generation
Sequencing (NGS)-Based In Vitro
Diagnostics (IVDs) Intended to Aid in
the Diagnosis of Suspected Germline
Diseases; Guidance for Stakeholders and
Food and Drug Administration Staff’’ to
the Office of the Center Director,
Guidance and Policy Development,
Center for Devices and Radiological
Health, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 66,
Rm. 5431, Silver Spring, MD 20993–
0002, or the Office of Communication,
Outreach, and Development, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
3128, Silver Spring, MD 20993–0002.
Send one self-addressed adhesive label
to assist that office in processing your
request.
VerDate Sep<11>2014
17:41 Apr 12, 2018
Jkt 244001
FOR FURTHER INFORMATION CONTACT:
Zivana Tezak, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4544, Silver Spring,
MD 20993–0002, 301–796–6206; or
OIRPMGroup@fda.hhs.gov; or Adam
Berger, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4547, Silver Spring,
MD 20993–0002, 240–402–1592; or
OIRPMGroup@fda.hhs.gov; or Stephen
Ripley, Center for Biologics Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 7301, Silver Spring,
MD 20993–0002, 240–402–7911.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is committed to implementing a
flexible and adaptive regulatory
approach to the oversight of NGS-based
tests, which will foster innovation and
simultaneously assure that patients have
access to accurate and meaningful test
results. FDA held two public workshops
on this issue: ‘‘Optimizing FDA’s
Regulatory Oversight of Next Generation
Sequencing Diagnostic Tests Public
Workshop’’ held on February 20, 2015,
and ‘‘Standards Based Approach to
Analytical Performance Evaluation of
Next Generation Sequencing In Vitro
Diagnostic Tests’’ held on November 12,
2016.
This guidance document provides
recommendations for designing,
developing, and establishing analytical
validity of NGS-based tests used for
WES or targeted human DNA
sequencing intended to aid in the
diagnosis of individuals with suspected
germline diseases or other conditions
(hereinafter referred to as ‘‘NGS-based
tests for germline diseases’’ or ‘‘NGSbased tests’’). It also outlines
considerations for possibly classifying
certain NGS-based tests for germline
diseases in class II and exempting them
from premarket notification
requirements. These recommendations
should be used as guidelines for test
developers for premarket submissions.
However, the longer term goal is for
these recommendations to form the
basis for standards that FDA could
recognize or for special controls and/or
conditions for premarket notification
(510(k)) exemption. FDA is also issuing
a guidance entitled ‘‘Use of Public
Human Genetic Variant Databases to
Support Clinical Validity for Genetic
and Genomic-Based In Vitro
Diagnostics’’ which is being issued
concurrently elsewhere in this issue of
the Federal Register.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
16107
On July 8, 2016, FDA announced a
draft guidance in the Federal Register
(81 FR 44614) and made available for
public comment. The comment period
closed on October 6, 2016. FDA
reviewed and considered all public
comments received and revised the
guidance, as appropriate.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on considerations for
design, development, and analytical
validation of NGS-based IVDs used to
aid in the diagnosis of suspected
germline diseases. It does not establish
any rights for any person and is not
binding on FDA or the public. You can
use an alternative approach if it satisfies
the requirements of the applicable
statutes and regulations. This guidance
is not subject to Executive Order 12866.
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by
downloading an electronic copy from
the internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm. This
guidance document is also available at
https://www.regulations.gov. Persons
unable to download an electronic copy
of ‘‘Considerations for Design,
Development, and Analytical Validation
of Next Generation Sequencing (NGS)Based In Vitro Diagnostics (IVDs)
Intended to Aid in the Diagnosis of
Suspected Germline Diseases; Guidance
for Stakeholders and Food and Drug
Administration Staff’’ may send an
email request to CDRH-Guidance@
fda.hhs.gov to receive an electronic
copy of the document. Please use the
document number 16009 to identify the
guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR part 807, subpart E, regarding
premarket notification submissions,
have been approved under OMB control
number 0910–0120; the collections of
information in 21 CFR part 801 and 21
CFR 809.10, regarding labeling, have
been approved under OMB control
E:\FR\FM\13APN1.SGM
13APN1
16108
Federal Register / Vol. 83, No. 72 / Friday, April 13, 2018 / Notices
number 0910–0485; the collections of
information in 21 CFR part 814,
subparts A through E, regarding
premarket approval, have been
approved under OMB control number
0910–0231; the collections of
information in 21 CFR part 820,
regarding the quality system regulation,
have been approved under OMB control
number 0910–0073; and the collections
of information in the guidance
document ‘‘Requests for Feedback on
Medical Device Submissions: The PreSubmission Program and Meetings with
Food and Drug Administration Staff’’
have been approved under OMB control
number 0910–0756.
Dated: April 9, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–07687 Filed 4–12–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–1111]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Permanent
Discontinuation or Interruption in
Manufacturing of Certain Drug and
Biological Products
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on ‘‘Permanent
Discontinuation or Interruption in
Manufacturing of Certain Drug and
Biological Products.’’
DATES: Submit either electronic or
written comments on the collection of
information by June 12, 2018.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before June 12, 2018.
The https://www.regulations.gov
daltland on DSKBBV9HB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:41 Apr 12, 2018
Jkt 244001
electronic filing system will accept
comments until midnight Eastern Time
at the end of June 12, 2018. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–N–1111 for ‘‘Permanent
Discontinuation or Interruption in
Manufacturing of Certain Drug and
Biological Products.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–5733, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
E:\FR\FM\13APN1.SGM
13APN1
]]>Agencies
[Federal Register Volume 83, Number 72 (Friday, April 13, 2018)]
[Notices]
[Pages 16106-16108]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-07687]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-D-1270]
Considerations for Design, Development, and Analytical Validation
of Next Generation Sequencing-Based In Vitro Diagnostics Intended To
Aid in the Diagnosis of Suspected Germline Diseases; Guidance for
Stakeholders and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of the final guidance entitled ``Considerations for
Design, Development, and Analytical Validation of Next Generation
Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) Intended to Aid in
the Diagnosis of Suspected Germline Diseases; Guidance for Stakeholders
and Food and Drug Administration Staff.'' FDA's vision is that NGS-
based tests can be developed, validated, and offered for clinical use
through a process that leverages appropriate standards, quality systems
controls, and community assessment of clinical validity to streamline
the premarket review process. This guidance provides recommendations
for designing, developing, and establishing analytical performance for
NGS-based tests used for whole exome human DNA sequencing (WES) or
targeted human DNA sequencing intended to aid in the diagnosis of
symptomatic individuals with suspected germline diseases or other
conditions. These recommendations are based on FDA's understanding of
the tools and processes needed to run an NGS-based test along with the
design and analytical validation considerations appropriate for such
tests.
DATES: The announcement of the guidance is published in the Federal
Register on April 13, 2018.
ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2016-D-1270 for ``Considerations for Design, Development, and
Analytical Validation of Next Generation Sequencing (NGS)-Based In
Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected
Germline Diseases; Guidance for Stakeholders and Food and Drug
Administration Staff.'' Received comments will be placed in the docket
and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including
[[Page 16107]]
the claimed confidential information, in its consideration of comments.
The second copy, which will have the claimed confidential information
redacted/blacked out, will be available for public viewing and posted
on https://www.regulations.gov. Submit both copies to the Dockets
Management Staff. If you do not wish your name and contact information
to be made publicly available, you can provide this information on the
cover sheet and not in the body of your comments and you must identify
this information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
An electronic copy of the guidance document is available for
download from the internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document entitled
``Considerations for Design, Development, and Analytical Validation of
Next Generation Sequencing (NGS)-Based In Vitro Diagnostics (IVDs)
Intended to Aid in the Diagnosis of Suspected Germline Diseases;
Guidance for Stakeholders and Food and Drug Administration Staff'' to
the Office of the Center Director, Guidance and Policy Development,
Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver
Spring, MD 20993-0002, or the Office of Communication, Outreach, and
Development, Center for Biologics Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3128,
Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to
assist that office in processing your request.
FOR FURTHER INFORMATION CONTACT: Zivana Tezak, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4544, Silver Spring, MD 20993-0002, 301-796-6206;
or [email protected]; or Adam Berger, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4547, Silver Spring, MD 20993-0002, 240-402-1592;
or [email protected]; or Stephen Ripley, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is committed to implementing a flexible and adaptive regulatory
approach to the oversight of NGS-based tests, which will foster
innovation and simultaneously assure that patients have access to
accurate and meaningful test results. FDA held two public workshops on
this issue: ``Optimizing FDA's Regulatory Oversight of Next Generation
Sequencing Diagnostic Tests Public Workshop'' held on February 20,
2015, and ``Standards Based Approach to Analytical Performance
Evaluation of Next Generation Sequencing In Vitro Diagnostic Tests''
held on November 12, 2016.
This guidance document provides recommendations for designing,
developing, and establishing analytical validity of NGS-based tests
used for WES or targeted human DNA sequencing intended to aid in the
diagnosis of individuals with suspected germline diseases or other
conditions (hereinafter referred to as ``NGS-based tests for germline
diseases'' or ``NGS-based tests''). It also outlines considerations for
possibly classifying certain NGS-based tests for germline diseases in
class II and exempting them from premarket notification requirements.
These recommendations should be used as guidelines for test developers
for premarket submissions. However, the longer term goal is for these
recommendations to form the basis for standards that FDA could
recognize or for special controls and/or conditions for premarket
notification (510(k)) exemption. FDA is also issuing a guidance
entitled ``Use of Public Human Genetic Variant Databases to Support
Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics''
which is being issued concurrently elsewhere in this issue of the
Federal Register.
On July 8, 2016, FDA announced a draft guidance in the Federal
Register (81 FR 44614) and made available for public comment. The
comment period closed on October 6, 2016. FDA reviewed and considered
all public comments received and revised the guidance, as appropriate.
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on considerations for design, development, and
analytical validation of NGS-based IVDs used to aid in the diagnosis of
suspected germline diseases. It does not establish any rights for any
person and is not binding on FDA or the public. You can use an
alternative approach if it satisfies the requirements of the applicable
statutes and regulations. This guidance is not subject to Executive
Order 12866.
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
downloading an electronic copy from the internet. A search capability
for all Center for Devices and Radiological Health guidance documents
is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. This
guidance document is also available at https://www.regulations.gov.
Persons unable to download an electronic copy of ``Considerations for
Design, Development, and Analytical Validation of Next Generation
Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) Intended to Aid in
the Diagnosis of Suspected Germline Diseases; Guidance for Stakeholders
and Food and Drug Administration Staff'' may send an email request to
[email protected] to receive an electronic copy of the
document. Please use the document number 16009 to identify the guidance
you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR part 807, subpart E, regarding
premarket notification submissions, have been approved under OMB
control number 0910-0120; the collections of information in 21 CFR part
801 and 21 CFR 809.10, regarding labeling, have been approved under OMB
control
[[Page 16108]]
number 0910-0485; the collections of information in 21 CFR part 814,
subparts A through E, regarding premarket approval, have been approved
under OMB control number 0910-0231; the collections of information in
21 CFR part 820, regarding the quality system regulation, have been
approved under OMB control number 0910-0073; and the collections of
information in the guidance document ``Requests for Feedback on Medical
Device Submissions: The Pre-Submission Program and Meetings with Food
and Drug Administration Staff'' have been approved under OMB control
number 0910-0756.
Dated: April 9, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-07687 Filed 4-12-18; 8:45 am]
BILLING CODE 4164-01-P
